Prospective Randomized Clinical Study on Transsphenoidal or Dopamine Drugs Therapy Treat Non-invasive Prolactinoma
Overview
- Phase
- Not Applicable
- Intervention
- transsphenoidal surgery treatment
- Conditions
- Prolactinoma
- Sponsor
- First Affiliated Hospital, Sun Yat-Sen University
- Enrollment
- 394
- Locations
- 1
- Primary Endpoint
- Endocrine remission rate
- Status
- Recruiting
- Last Updated
- 8 years ago
Overview
Brief Summary
the study aim to investigate the endocrine remission rate of non-invasive prolactinoma between transsphenoidal surgery treatment and Dopamine agonist treatment.
Detailed Description
Non-invasive prolactinomas were treated by transsphenoidal surgery or Dopamine agonist until now. However，this two type therapies were controversial. The study aim to investigate the endocrine remission rate of non-invasive prolactinoma between transsphenoidal surgery treatment and Dopamine agonist treatment.
Investigators
Hai-Jun Wang
director
First Affiliated Hospital, Sun Yat-Sen University
Eligibility Criteria
Inclusion Criteria
- •non-invasive prolactionma
Exclusion Criteria
- •invasive prolactioma
Arms & Interventions
transsphenoidal surgery treatment
Transsphenoidal surgery treat non-invasive prolactinoma by experienced neurosurgeon
Intervention: transsphenoidal surgery treatment
dopamine agonist treatment
Minimum effective dose of dopamine agonist, bromocriptine, treat non-invasive prolactinoma
Intervention: dopamine agonist treatment
Outcomes
Primary Outcomes
Endocrine remission rate
Time Frame: five-year
After intervention, blood prolactin normalization rate